Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human immunodeficiency virus (HIV) RNA and genome sequences represent critical therapeutic targets for curing or achieving long-term functional control of HIV-1 infection. The HIV genome consists of single-stranded RNA in the virion, which is reverse-transcribed into double-stranded proviral DNA and integrated into the host cell genome, establishing a persistent latent reservoir that is unaffected by standard antiretroviral therapy (ART). Novel therapeutic strategies directly target these viral nucleic acid sequences to either excise the integrated provirus or silence viral gene expression. For instance, CRISPR/Cas9-based therapies like EBT-101 utilize guide RNAs to make precise cuts in the integrated HIV genome, aiming to excise replication-competent proviral DNA. Additionally, RNA-based approaches, including short hairpin RNAs (shRNAs like PromA), antisense oligonucleotides (ASOs), and ribozymes, target viral transcripts to induce post-transcriptional gene silencing, transcriptional gene silencing, or RNA degradation. While these approaches offer a potential path toward a functional cure, significant challenges remain, including the risk of off-target editing, incomplete clearance of the latent reservoir leading to viral rebound, and the rapid emergence of viral escape mutants due to the high mutation rate of HIV.
Gene editing (CRISPR/Cas9-mediated excision of proviral DNA), RNA interference (shRNA/siRNA-mediated post-transcriptional gene silencing or transcriptional gene silencing), antisense oligonucleotide-mediated RNase H cleavage or steric hindrance, and decoy RNA-mediated sequestration of viral proteins.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunodeficiency virus RNA/genome sequences (HIV RNA).